Press Release - Ancillare, LP

Ancillare Opens New Distribution Facility in the Netherlands for the EU Clinical Trial Ancillary Supply Chain

Nov 9, 2020 | Press Release

Ancillare, the world leader in Clinical Trial Ancillary Supply Chain (CTASC™), announced that its new Distribution Facility will open December 1.

Horsham, Pa. — November 9th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it will open a new Distribution Facility in the Netherlands on December 1, 2020.

Ancillare currently holds over a dozen strategic depots to manage the flow of supplies to clinical trial sites around the globe. In addition to Ancillary Supply Chain storage and distribution, the new facility will be home to Ancillare’s European headquarters.

“We are proud to expand our global footprint through our new Netherlands facility,” said Dr. Joanne Santomauro, Chief Executive Officer. “This strategic distribution hub will allow for more streamlined Clinical Trial Ancillary Supply Chains across Europe, and will help us continue reaching more trial sites, and patients, around the world.”

Over the past several months, Ancillare’s global operations teams have worked diligently to ensure that the new facility opens successfully on December 1. The company has obtained all necessary licenses and approvals for business operations in the EU, and is working to ensure a seamless transition for Sponsors.

To learn more about Ancillare’s Global Distribution Network, visit Ancillare.com/About.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Appoints Dr. John Fitzgerald to Medical Director

Oct 29, 2020 | Press Release

John Fitzgerald, DO, FACOG, joins Ancillare as Medical Director to lend clinical expertise to Clinical Trial Ancillary Supply Chains™.

Horsham, Pa. — October 29th, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed John Fitzgerald, DO, FACOG as Medical Director to serve on its growing Clinical Development Team.

Dr. Fitzgerald will consult with Ancillare’s cross-functional teams to ensure compliant ancillary supply chains during the clinical study design and execution phases and will also collaborate directly with trial Sponsors to provide his clinical expertise.

A practicing obstetrician and gynecologist in the Philadelphia area for over three decades, Dr. Fitzgerald also serves as the Associate Director/Associate Professor for the Physician Assistant Program at Salus University. He has published a number of research articles on a variety of women’s health topics as well as a lead investigator for the National HPV Study.

“We are pleased to bring on Dr. Fitzgerald as a Medical Director,” said Dr. Joanne Santomauro, Chief Executive Officer. “For the past fifteen years, Ancillare has solved countless complex supply challenges for our Sponsors. Dr. Fitzgerald and the entire Clinical Development Team are critical to expanding Ancillare’s value offering through their specialized clinical knowledge and experience.”

To read full biographies of Ancillare’s Medical Directors and learn more about the company’s Subject Matter Experts, visit https://www.ancillare.com/about/#leadership.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Ancillare Wins Multi-Million Dollar Contracts with Top Pharmaceutical Companies; Partners on Fifteen COVID-19 Trials

Sep 15, 2020 | Press Release

Ancillare, the Industry leader in Clinical Trial Ancillary Supply Chain™, captures several multi-million dollar contracts during the COVID-19 pandemic.

HORSHAM, Pa. — September 15, 2020. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has closed several multi-million dollar three-to-five year contracts with major global pharmaceutical companies.

The series of large wins marks another step toward Ancillare’s diversification goals, which aim to grow its offerings worldwide. Earlier this year, the company announced it had secured a multi-million dollar debt financing deal with Fulton Bank, which enabled progress toward enhancing its technology services, expanding to new verticals, and beginning to execute a long-term acquisitions strategy.

“This milestone reflects Ancillare’s orientation toward growth and creates further opportunities to expand our services,” said Dr. Joanne Santomauro, Chief Executive Officer. “In tandem with the long-term, structured capital we’ve secured, these new contracts support our commitment to deliver innovation across the supply chain and throughout the entire clinical trial space.”

The new business wins add to Ancillare’s extensive portfolio, which now includes fifteen ongoing COVID-19 trials for which the company is providing CTASC management.

“With the urgency the pandemic has imposed on the pharmaceutical world, clinical trial Sponsors need reliable supply and equipment solutions,” Santomauro added. “We attribute our recent successes to the fact that we are not just another supplier, but instead a true partner with a consultative and forward-thinking approach. These wins are a testament to Ancillare’s end-to-end consultative approach to CTASC.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com

Ancillare Launches Redesigned Website, Featuring Custom Ancillary Supply Solutions for Clinical Trial Sponsors and Research Organizations

Jul 30, 2020 | Press Release

Ancillare, the industry leader in Clinical Trial Ancillary Supply Chain™, announces the official launch of its new website.

HORSHAM, Pa. — July 30, 2020. Global Clinical Trial Ancillary Supply Chain™ leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced the re-launch of its website, Ancillare.com.

The new website features a newly-designed interface, showcasing Ancillare’s unique approach, service offerings as well as its custom-built suite of technology solutions. The design streamlines the user experience through clean and modernized visuals, responsive elements, and consolidated content.

In its launch announcement to clients, Ancillare described the redesign as a reinforcement of its mission since 2006: “to deliver complex ancillary supply chains, simply and with a singular focus.”

“We are thrilled to share our new website with our industry partners and the world,” said Dr. Joanne Santomauro, Chief Executive Officer. “The Clinical Trial Ancillary Supply Chain, or CTASC, is a highly complex field. This platform serves to present the clearest picture of who we are and what we do, while highlighting our suite of technology solutions.”

The website launch follows a number of other announcements from the company this year, including several additions to its Leadership Team, as well as plans for acquisitions and growth. The company also announced the rollout of the Ancillare Digital Communications Platform (ADCP), built to give Sponsors and their partners predictive insights into the CTASC for their portfolio of studies.

“Strengthening our web presence is one of many exciting steps we’re taking to grow as the leader in the global Clinical Trial Ancillary Supply Chain,” Santomauro added. “We are eager to continue innovating, and to optimize the Sponsor experience worldwide.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com

Ancillare Closes Debt Financing with Fulton Bank, Looks Toward Diversification and Growth

May 13, 2020 | Press Release

Ancillare, a diversity supplier for the Clinical Trial Ancillary Supply Chain™, secures capital amidst the COVID-19 pandemic.

HORSHAM, Pa. — May 13, 2020. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the first organization exclusively serving the end-to-end ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has closed a multi-million dollar debt financing deal with Fulton Bank.

“To secure funds in debt financing in the midst of the COVID-19 pandemic is a significant accomplishment,” said Dr. Joanne Santomauro, Chief Executive Officer. “It presents an exciting opportunity to further shape the future of the Clinical Trial Ancillary Supply Chain at a time when innovation couldn’t be more critical.”

Ancillare, a WBENC certified woman-owned business, has serviced the global Clinical Trial Ancillary Supply Chain (CTASC™) for nearly 15 years. The new funds will enable progress towards the organization’s growth initiatives as well as the company’s long-term diversification strategies. The financing presents an opportunity for Ancillare to strengthen its technology platform with robust data and predictive analytics programs, expand its global footprint with new vertical offerings, and enhance customer experiences across all services. Additionally, the company plans to initiate an acquisition strategy to further expand globally.

“Fulton Bank is committed to expanding our specialization in the Life Sciences and Technology industry. Our relationship with Ancillare is an opportunity for us to support a thriving local life sciences organization that is performing a critical function during this worldwide health care crisis,” said Lou Lombardi, Southeastern Pennsylvania commercial market executive and senior vice president for Fulton Bank. “Providing these funds enables innovation, which gives hope for a healthier future.”

“I have full confidence in Fulton – the bank is an excellent partner, and one who understands our business,” Santomauro added. “Fulton Bank embraces our company’s mission and vision which in turn will result in Ancillare’s ability to deliver quicker, better, and more efficient programs to our sponsors.”

As a diversity supplier and strategic partner to many of the top global pharmaceutical and biotechnology companies, Ancillare’s current initiatives are largely focused on developing technology-based solutions for its clients. Recently, the company announced the launch of its Digital Communications Platform, which gives sponsors and their partners predictive insights into the CTASC for their portfolio of studies. The funds secured in partnership with Fulton Bank will allow Ancillare to expand its technology offerings and execute forward-thinking, industry-shaping initiatives.

About Ancillare, LP
Ancillare is the first organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with corporate offices in the United States and United Kingdom, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

About Fulton Bank, NA
Fulton Bank, N.A. is a subsidiary of Fulton Financial Corporation, a $22 billion Lancaster, Pa.-based financial holding company, has approximately 3,600 employees and operates approximately 230 branches in Pennsylvania, Maryland, Delaware, New Jersey and Virginia through Fulton Bank, N.A. Additional information on Fulton Bank can be found at www.fultonbank.com.

Ancillare Launches Digital Communications Platform

Apr 8, 2020 | Press Release

HORSHAM, Pa.— Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the first organization exclusively serving the end-to-end ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced the launch of its new Ancillare Digital Communications Platform (ADCP).

ADCP is an interactive communications Portal that marries Ancillare’s 16 years of rich clinical trial ancillary supply data with AI, analytics, and collaboration technology. The Platform will provide sponsors with real time predictive insights into the Clinical Trial Ancillary Supply Chain (CTASC).

This Platform, built by Ancillare’s technology team, will offer sponsors a central access point to track the flow of ancillary supplies in their clinical trials. Its key capabilities will include inventory information and alerts, shipment tracking, real-time document collaboration, trend analysis and forecasting, EDI and sponsor single sign-on functionality.

The announcement follows the appointment of Ancillare’s new Vice President of Global Information Technology and Infrastructure, Deighton Liverpool. Under his guidance, Ancillare’s leadership team is executing on plans to further streamline the ancillary supply chain through innovative technologies.

“The launch of ADCP marks a critical moment in Ancillare’s history,” said Dr. Joanne Santomauro, Chief Executive Officer. “Our goal to become a technology-driven supply chain organization relies on the ability to integrate our industry-defining process with forward-thinking technologies.”

In the coming weeks, Ancillare will make the first version of ADCP available to its clients. The organization plans to expand upon the core functionalities later in 2020. For future updates regarding ADCP, please visit ancillare.com